Researchers have reported the first successful visualisation of pathological alpha-synuclein aggregates in the living human brain using a novel positron emission tomography (PET) tracer, a development that could transform the diagnosis and monitoring of Parkinson’s disease and related neurodegenerative disorders. The study, published in Science Translational Medicine, describes the development and validation of [11C]MODAG-005, a…
Category: Movement Disorders
Teva files FDA application for ecopipam in paediatric Tourette syndrome
Teva Pharmaceutical Industries has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ecopipam, an investigational treatment for paediatric Tourette syndrome. The company says the submission marks a significant milestone for what could become the first new FDA-approved therapy for children and adolescents with Tourette syndrome in more than…
NeuraLight completes international multicentre Parkinson’s clinical trial
NeuraLight has announced the completion of PALOMA, an international multicentre clinical trial evaluating eye movement based biomarkers as a tool for monitoring disease progression in Parkinson’s disease. The 12-month longitudinal study followed around 300 participants across clinical sites in the US and Europe, making it one of the largest studies to date examining oculometric measures…
Cure Parkinson’s opens new funding call for up to £300k
Cure Parkinson’s International Linked Clinical Trials (iLCT) Pipeline Research Acceleration Programme is welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. Each year, a committee of over 20 world-leading Parkinson’s experts meet to evaluate, rank, and prioritise potentially disease-modifying drugs for Parkinson’s as part of their iLCT programme. The goal of this initiative…
Bial reports major progress in phase 2b trial for GBA1-associated Parkinson’s disease
Bial has announced a key operational milestone in its ongoing phase 2b ACTIVATE study evaluating BIA 28-6156 in patients with Parkinson’s disease associated with mutations in the GBA1 gene. The company confirmed that 75% of enrolled patients have now completed the double-blind treatment period through week 78. The ACTIVATE study is assessing the efficacy, safety,…
Bial launches KYNMOBI in the UK for Parkinson’s OFF episodes
Bial has announced the launch of KYNMOBI (apomorphine hydrochloride) in the United Kingdom, introducing the first sublingual film for the intermittent treatment of uncontrolled OFF episodes in adults with Parkinson’s disease whose symptoms are not adequately controlled by oral anti-Parkinson medication. Around 166,000 people in the UK are estimated to be living with Parkinson’s disease,…
Bringing together international leaders of Parkinson’s platform trials
Stakeholders involved in the setup and running of Parkinson’s platform trials met recently for the second annual International PD-Platform Meeting, leading to the launch of the Global Alliance for Parkinson’s Platforms (GAPP). Representatives from the UK, France, the US, Norway, and Australia have joined this new international initiative. GAPP has been created through collaboration between…
Update on AMT-130 for Huntington’s disease
uniQure N.V, a gene therapy company advancing transformative therapies for patients with severe medical needs, announced on November 3rd 2025 that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD). Based on the discussions at…
Immediate motor gains in tremor-dominant Parkinson’s disease
MR-guided ultrasound targets PTT circuit A new study in the European Journal of Neurology highlights the immediate therapeutic impact of stepwise dual-target MR-guided focused ultrasound (dtMRgFUS) in treating tremor-dominant Parkinson’s disease. This approach targets both the ventral intermediate nucleus (VIM) and the pallidothalamic tract (PTT) in a single session. Twenty patients (mean age 69.3 ± 8.9 years)…
Metabolic syndrome increases risk of Parkinson’s disease
Having a larger waistline, high blood pressure and other risk factors that make up metabolic syndrome is associated with an increased risk of Parkinson’s disease, according to a study published on August 20, 2025, in Neurology®, the medical journal of the American Academy of Neurology. The study does not prove that metabolic syndrome causes Parkinson’s disease; it…
